Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152307 | 0.97 | HTR7 (0.33) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1152556 | 0.92 | CYP1A2 (0.33) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1152893 | 0.89 | HTR7 (0.33) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1152812 | 0.87 | CNR2 (0.35) | MAPTJAK2KCNH2 | |
| SCHEMBL6295433 | 0.85 | JAK2 (0.32) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 | |
| SCHEMBL1152030 | 0.85 | MPO (0.33) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1153156 | 0.85 | MMP14 (0.34) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1153323 | 0.85 | MPO (0.33) | HTR7CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1152499 | 0.84 | MAPT (0.34) | CYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1152916 | 0.84 | CYP1A2 (0.32) | CYP1A2MAPTCYP2C19KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | claimed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-6969721-B2 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | BRISTOL-MYERS SQUIBB PHARMA (US) | 2005-11-29 | — | — | US | disclosed |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | RODGERS JAMES D (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596729-B2 | Especially in combination with one or more HIV reverse transcriptase inhibitors, HIV protease inhibitors, fusion inhibitors, and/or CCR-5 | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | DUPONT PHARMACEUTICALS COMPANY | 2002-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | HTR7 4258/4885CYP1A2 3895/4885MAPT 1583/4885 |
| US-20040023955-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | HTR7 1449/4885CYP1A2 403/4885MAPT 1600/4885 |
| US-20020107261-A1 | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors | TYMP, POLRMT, DPYD | HTR7 1449/4885CYP1A2 403/4885MAPT 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.